April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
"An aqueous clear cyclosporine-A topical drops for retinal delivery"
Author Affiliations & Notes
  • Kishore Cholkar
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Brian C Gilger
    Department of Clinical Sciences, North Carolina State University, Raleigh, NC
  • Poonam Velagaleti
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Sidney L Weiss
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Ashim K Mitra
    Pharmaceutical Sciences, Univ of Missouri Kansas City, Kansas City, MO
  • Footnotes
    Commercial Relationships Kishore Cholkar, Auven Therapeutics (C); Brian Gilger, Auven Therapeutics (C); Poonam Velagaleti, Auven Therapeutics (C); Sidney Weiss, Auven Therapeutics (F); Ashim Mitra, Auven Therapeutics (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 451. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kishore Cholkar, Brian C Gilger, Poonam Velagaleti, Sidney L Weiss, Ashim K Mitra; "An aqueous clear cyclosporine-A topical drops for retinal delivery". Invest. Ophthalmol. Vis. Sci. 2014;55(13):451. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The objectives of this study are to (i) prepare, optimize and characterize cyclosporine-A (Cys-A) loaded mixed nanomicellar (MMF) aqueous drops (ii) determine the in vivo ocular toxicity and tolerability of Cys-A MMF and (iii) to determine ocular tissue distribution of Cys-A after single and multiple Cys-A MMF topical drop administration and compare with Restasis®.

Methods: Cys-A MMF were prepared following solvent evaporation technique. MMF Size, polydisperisit index, surface potential, shape, qualitative proton nuclear magnetic resonance (1H NMR), critical micellar concentration (CMC), MMF entrapment and loading studies were studied to characterize the MMF. In vitro cytotoxicity studies were conducted in rPCEC and D407 cells with single and multiple dosing of Cys-A MMF. Similarly, tolerability and toxicity studies were studied in rabbits with topical drop instillation. In vivo ocular Cys-A tissue distribution were studied in rabbits with single and multi drop instillation. Cys-A in the individual ocular tissue was quantified with sensitive LC-MS/MS analysis.

Results: Cys-A was loaded into MNF to generate an overall loading of 1 mg/mL. CMC for the MMF was found to be 7.07 x 10-3 wt%. Optimized MMF demonstrated high drug loading and entrapment efficiency. Average MMF size was found to be ~20 nm with narrow polydispersity index (0.147). TEM studies showed MMF to be spherical with smooth surface morphology. Absence of free or unentrapped Cys-A in MMF was confirmed by 1H NMR spectroscopy. Cytotoxicity studies on rPCEC and D407 cells indicated MMF to be safe. Similarly, ocular tolerability and toxicity studies in rabbits demonstrated the formulation to be safe and well tolerated. There was observed no difference in the intraocular pressure before and after treatment. Histological studies demonstrated no toxicologic or inflammatory changes in the anterior (conjunctiva / cornea / iris) or posterior segments (vitreous / retina) of the eye indicating the formulation to be safe. In vivo Cys-A ocular tissue distribution studies with topical drops showed higher Cys-A concentrations (~53.7 ng/g tissue) in retina-choroid relative to Restasis (~3.76 ng/g tissue).

Conclusions: A clear aqueous safe and well-tolerated Cys-A loaded MMF is prepared and evaluated in preclinical studies. High levels of Cys-A was quantified in back of the eye tissues with topical drop instillation into cul-de-sac.

Keywords: 489 cyclosporine • 607 nanotechnology • 608 nanomedicine  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×